Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease (CVD) associated with enhanced atherothrombosis is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) (1). Platelet hyperactivity in conjunction with endothelial dysfunction contributes to accelerated atherothrombosis in T2DM (1–3). The enhanced platelet reactivity in T2DM is caused by several factors including insulin resistance and chronic hyperglycemia (1–3). Although more intensive glycemic control has been shown to reduce the long-term risk of CVD, this treatment is often associated with weight gain and hypoglycemia (4,5). Thus, the development of novel antihyperglycemic agents without these negative side effects is needed. In this regard, incretin-based therapies have emerged as important agents in the treatment of T2DM (6). One such incretin therapy is glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) such as exenatide that provide supraphysiological concentrations of GLP-1 that stimulate GLP-1Rs (7–9). Another is dipeptidyl peptidase 4 (DPP-4) inhibitors, which prevent the proteolytic breakdown and inactivation of GLP-1 (6). Both GLP-1RAs and DDP-4 inhibitors improve glycemic control, reduce weight, and limit the risk of hypoglycemia, and thus they are regarded as therapeutic options for glycemic therapy in T2DM. The clinical trials in T2DM patients with DPP-4 inhibitors and GLP-1RAs suggest that incretin-based therapies generally have neutral CVD outcome profiles in patients with T2DM except for adverse outcomes for …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin
Brain, S. D., & Grant, A. D. (2004) · Physiological Reviews · doi:10.1152/physrev.00037.2003 · Cited by 765
Cited by
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Metadata
- Authors
- Jia, G., Aroor, A. R., & Sowers, J. R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-05-18
- Volume
- 65
- Issue
- 6
- Pages
- 1487-1489
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2396291855
- Cited by
- 27
- References
- 2
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.